Day OneTuesday, 29 April 2025 - GMT (Greenwich Mean Time, GMTZ)

M&A Masterclass

Part 1: Deep Dive into the Current M&A Landscape

• Overview of the Pharma M&A Landscape
  • Current trends and statistics in pharma M&A
  • Impact of recent M&A deals on the industry
• Importance of M&A for Biotechs
  • How M&A can provide biotechs with resources, market access, and expertise
  • Strategies for biotechs to position themselves as attractive targets or acquirers
• Key Considerations for Successful Transactions
  • Essential elements of due diligence, valuation methods, and metrics
  • Importance of cultural fit and post-acquisition integration

Part 2: How to Turn a 10-Person Biotech into a $1.1Bn Acquisition in 7 Years

Presented by Renee Aguiar-Lucander, CEO, Calliditas

• Motivation Behind the Acquisition
• Process Overview
• Outcome and Lessons Learned
• Future Considerations

Part 3:

• Open Floor for Questions
  • How to prepare a biotech company for M&A discussions?
  • What specific attributes do buyers look for in a biotech firm?
  • How can biotechs leverage M&A as a growth strategy?
• Wrap-Up Discussion
  • Summarize key takeaways from the workshop.
  • Highlight actionable insights for biotech companies considering M&A

IPO Masterclass

Part 1: Understanding the IPO Landscape

• Overview of the IPO Market
  • Current trends and statistics in biotech IPOs
  • Key factors driving IPO activity in the sector
• Advantages and Challenges of Going Public
  • Access to capital, visibility, and credibility benefits
  • Regulatory, operational, and financial challenges associated with IPOs
• Pre-IPO Preparation
  • Key steps to ensure readiness, including financial audits and governance

Building a compelling investment story for investors

Part 2:

How to Take Your Company Public: Insights and Strategies for Biotech Success

1. When is the right time for a biotech to go public, and what are the key steps to prepare?
2. How can companies navigate complex financial and regulatory environments across global markets?
3. What do investors look for, and how can biotechs build trust and confidence with them?
4. What are the most common pitfalls during the IPO process, and how can they be avoided?

Speaker: Linda McGoldrick, Board Director, Alvotech

Part 3:

Q&A and Discussion

• Open Floor for Questions
  • What are the most critical factors to consider when deciding to go public?
  • How should a biotech company approach investor relations post-IPO?
  • What are the best practices for maintaining stock performance after going public?
• Wrap-Up Discussion
  • Summarize the key insights and takeaways from the workshop
  • Highlight actionable steps for biotech companies in preparing for an IPO